Haemonetics Corporation, a leading player in medical technology specializing in breakthrough healthcare solutions for enhanced patient outcomes, has disclosed a definitive pact to divest its whole blood assets to GVS, S.p.A (GVS). GVS stands as a prominent manufacturer of filtration systems, particularly in the healthcare and life sciences industries. This agreement amounts to a potential $67.1 million in cash, consisting of an initial $44.6 million and additional contingent earnings up to $22.5 million over the next four years. Haemonetics plans to utilize the proceeds from this deal for general corporate uses and to fund its growth strategies.
In accordance with this agreement, GVS will take over Haemonetics’ entire range of proprietary whole blood collection, processing, and filtration systems. This includes the acquisition of the company’s production site in Covina, California, utilized for some of these products, along with associated equipment and resources at the Tijuana, Mexico facility. The closure of this transaction is anticipated in the first quarter of 2025, contingent upon standard closing conditions.
Haemonetics’ Blood Center wing maintains its commitment to producing and distributing its comprehensive array of apheresis solutions dedicated to automated blood collection. These resources include devices and single-use kits that cater to various apheresis collections, such as platelets, plasma, and red cells, ensuring optimum operations in blood centers.
This transaction is in line with Haemonetics’ 2020 agreement to transfer its Fajardo, Puerto Rico manufacturing site to GVS and to establish a prolonged supply and development arrangement granting GVS exclusive access to fabricate and provide the proprietary blood filters from the Fajardo site for Haemonetics.
Chris Simon, the president and chief executive officer of Haemonetics, commented, “As part of our strategic plan, we are concentrating on evolving our portfolio to reinforce our leadership in both commercial and non-commercial plasma segments while expanding our footprint in rapidly growing hospital markets. Our agreement with GVS builds on our longstanding relationship and will ensure a seamless transition for Haemonetics’ global whole blood clientele, in alignment with our corporate objectives.”
Haemonetics operates as a global healthcare entity committed to delivering a comprehensive range of innovative medical products and solutions designed to help clients advance patient care and lower healthcare costs.